Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes

Biomarker Assessment of HR Deficiency, TumorBRCA1/2Mutations, andCCNE1Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy

(2018) Euan A. Stronach et al.   MOLECULAR CANCER RESEARCH

Tumor molecular profiling to differentiate extreme responses to first-line platinum-based chemotherapy in suboptimally debulked serous ovarian cancer patients.

(2018) Johanne I Weberpals et al.   JOURNAL OF CLINICAL ONCOLOGY

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) Robert L Coleman et al.   LANCET

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

(2017) Elizabeth M Swisher et al.   LANCET ONCOLOGY

Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer

(2017) et al.   JAMA Oncology

Expression of potential biomarkers associated with homologous recombination repair in patients with ovarian or triple-negative breast cancer

(2016) Hiroyuki Nomura et al.   Cancer Biomarkers

Ovarian Cancers Harboring Inactivating Mutations inCDK12Display a Distinct Genomic Instability Pattern Characterized by Large Tandem Duplications

(2016) Tatiana Popova et al.   CANCER RESEARCH

No evidence that protein truncating variants inBRIP1are associated with breast cancer risk: implications for gene panel testing

(2016) Douglas F Easton et al.   JOURNAL OF MEDICAL GENETICS

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

(2016) Mansoor R. Mirza et al.   NEW ENGLAND JOURNAL OF MEDICINE

Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action

(2016) Y. Pommier et al.   Science Translational Medicine

Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors

(2015) Christopher J. Lord et al.   Annual Review of Medicine

Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer

(2015) Susan J. Ramus et al.   JNCI-Journal of the National Cancer Institute

Whole–genome characterization of chemoresistant ovarian cancer

(2015) Ann-Marie Patch et al.   NATURE

Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer

(2015) Susan J. Ramus et al.   JNCI-Journal of the National Cancer Institute

Abstract 4420: Generating preclinical models to assess bone marrow toxicity induced by the PARP inhibitor olaparib in combination with chemotherapy.

(2014) Mark J. O'Connor et al.   CANCER RESEARCH

Ovarian Cancer-associated Mutations Disable Catalytic Activity of CDK12, a Kinase That Promotes Homologous Recombination Repair and Resistance to Cisplatin and Poly(ADP-ribose) Polymerase Inhibitors

(2014) Poorval M. Joshi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

(2014) Jonathan Ledermann et al.   LANCET ONCOLOGY

BRCA and Early Events in the Development of Serous Ovarian Cancer

(2014) Sophia H. L. George et al.   Frontiers in Oncology

BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study

(2013) J L Lesnock et al.   BRITISH JOURNAL OF CANCER

Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity

(2013) I. Bajrami et al.   CANCER RESEARCH

Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas

(2013) Kathryn P. Pennington et al.   CLINICAL CANCER RESEARCH

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

(2013) Garrett M Frampton et al.   NATURE BIOTECHNOLOGY

Validation of the BRCA1 antibody MS110 and the utility of BRCA1 as a patient selection biomarker in immunohistochemical analysis of breast and ovarian tumours

(2013) Roy Milner et al.   VIRCHOWS ARCHIV

Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer

(2012) V Abkevich et al.   BRITISH JOURNAL OF CANCER

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

(2012) Jonathan Ledermann et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes

(2011) D. Blazek et al.   GENES & DEVELOPMENT

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

(2011) Karen A Gelmon et al.   LANCET ONCOLOGY

Mutations in BRIP1 confer high risk of ovarian cancer

(2011) Thorunn Rafnar et al.   NATURE GENETICS

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

(2010) Andrew Tutt et al.   LANCET

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

(2010) M William Audeh et al.   LANCET

Targeted therapy for cancer using PARP inhibitors

(2008) Christopher J Lord et al.   CURRENT OPINION IN PHARMACOLOGY